XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenues $ 666.2 $ 596.2
Operating expenses:    
Salaries and benefits 202.2 178.9
Supplies 188.4 171.6
Professional and medical fees 74.6 63.6
Lease expense 21.4 20.0
Other operating expenses 45.6 37.3
Cost of revenues 532.2 471.4
General and administrative expenses 32.0 29.5
Depreciation and amortization 33.7 27.4
Transaction and integration costs 12.5 7.1
Grant funds (1.1) (1.2)
Net loss (gain) on disposals, consolidations and deconsolidations 10.5 (0.1)
Equity in earnings of unconsolidated affiliates (3.3) (3.1)
Litigation settlements 3.0 (32.8)
Other expense (income), net 0.3 (2.4)
Total operating expenses 619.8 495.8
Operating income 46.4 100.4
Interest expense, net (46.8) (56.3)
(Loss) income before income taxes (0.4) 44.1
Income tax benefit (expense) 1.6 (1.3)
Net income 1.2 42.8
Less: Net income attributable to non-controlling interests (26.1) (30.6)
Net (loss) income attributable to Surgery Partners, Inc. $ (24.9) $ 12.2
Net (loss) income per share attributable to common stockholders    
Basic (in USD per share) $ (0.20) $ 0.14
Diluted (in USD per share) [1] $ (0.20) $ 0.14
Weighted average common shares outstanding    
Basic (shares) 125,206 87,995
Diluted (shares) [1] 125,206 90,272
[1] The impact of potentially dilutive securities for the three months ended March 31, 2023 was not considered because the effect would be anti-dilutive.